Sysmex: and JCR Pharmaceuticals establish a joint venture in the field of regenerative medicine and cell therapy – aimed at the research and development and early commercialization of regenerative medicine products using stem cells, etc. –

In recent years, the significant potential of regenerative medicine and cell therapy has been established particularly in areas traditionally difficult to address with conventional chemically synthesized low molecular weight drugs.1 or biopharmaceutical,2 such as restoring tissues and functions lost due to aging, disease, autoimmune diseases or cancer. In particular, research and development on the therapeutic application of stem cells, including hematopoietic stem cells, mesenchymal stem cells, and iPS cells, have received considerable attention.

Since its inception, Sysmex has provided network solutions using IoT (Internet of Things) and automated test workflows to improve the safety of healthcare professionals and for the optimization of operational efficiency in clinical laboratories. Additionally, while providing quality control testing to companies that develop regenerative medicine products, Sysmex has conducted research and development related to new pre-transplant compatibility tests examining the patient’s immune response against the organ or the tissue to be transplanted.

Since its inception, JCR has been engaged in the research, development, manufacture and sale of pharmaceutical products using regenerative medicine, genetic engineering and gene therapy technologies to advance therapies in the field of rare diseases. This is exemplified in the field of regenerative medicine, by the endorsement of TEMCELL® Inj. HS,3 the first allogeneic regenerative medicine in Japan (Common name: mesenchymal stem cells derived from human bone marrow (allogeneic)) in February 2016 for the treatment of acute graft-versus-host disease (acute GVHD),4 a serious complication that develops after a hematopoietic stem cell transplant. Over the past several years, JCR has further streamlined and integrated its expertise around creating breakthrough medicines for the advancement of highly innovative medicines that could not be developed without these breakthrough technologies.

In the joint venture, the two companies aim to realize the social implementation of regenerative medicine and cell therapy by integrating Sysmex’s expertise in quality control testing technology and knowledge of flow efficiency. using robotic technology, including IoT, with JCR’s expertise in development, manufacturing and marketing. regenerative medicine products. AlliedCel Corporation, which is the corporate name of the joint venture following prior discussions regarding the alliance of the two companies, was established on October 3, 2022. The joint venture will advance the programs of technology development and commercialization potential, including the project currently promoted by the two companies using hematopoietic stem cell proliferation technology.

The AlliedCel name represents the joint venture’s aspiration to integrate the knowledge and expertise of a wide range of collaborators and stakeholders, including business partners, patients and their families, with the common goal of unleashing the power cells to support patients in their life needs. change therapies. Through research and development of regenerative medicine products using various cells such as stem cells, AlliedCel aims to provide appropriate treatment options to patients and improve their prognosis.

Joint venture profile

Company Name:

AlliedCel Corporation


1-5-5 Minatojimaminami-machi, Chuo-ku, Kobe, Hyogo, Japan


October 3, 2022


100 million yen

Capital reserve:

100 million yen

Investment rate:

Sysmex 50%, JCR 50%

Executive officers:

President: Hiroyuki Sonoda

(Vice President, Research and Corporate Strategy, Executive Director of Research Division, JCR Pharmaceuticals Co., Ltd.)

Executive Vice President, Member of the Management Board: Kenji Tsujimoto

(Executive Vice President of Technology Strategy Division, Sysmex Corporation)

Commercial content:

Research and development, manufacture and sale of regenerative medicine products

Settlement period:


About Sysmex Corporation

In line with its mission of “Shaping the Advancement of Healthcare”, which is defined in the “Sysmex Way”, the corporate philosophy of the Sysmex Group, Sysmex strives to contribute to the development of healthcare and the healthy life of people. Sysmex conducts integrated R&D, manufacturing and sales activities, and provides support services for its instruments, reagents and software for in vitro blood, urine and other bodily fluid tests. Sysmex supplies its products to medical institutions in more than 190 countries and regions around the world. Over the past few years, Sysmex has expanded its life sciences business, using proprietary technologies to create new testing and diagnostic values, realize optimized healthcare for individual patients, help reduce patient burden and improve their quality of life.

Company profile

Last name:

Sysmex Company


1-5-1 Wakinohama-kaigandori, Chuo-ku, Kobe, Hyogo, Japan


February 20, 1968

Paid-up capital:

JPY 14.112 million (as of March 31, 2022)

Activity area:

Development, manufacture, sale and export/import of diagnostic instruments, reagents and related software


About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is an international specialty pharmaceutical company redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build on our 48-year legacy in Japan while expanding our global footprint in the United States, Europe and Latin America. We improve the lives of patients by applying our scientific expertise and unique technologies to research, develop and deliver next-generation therapies. JCR strives to expand possibilities for patients while accelerating medical progress globally. Our core values ​​- reliability, trust and persistence – benefit all of our stakeholders, including employees, partners and patients. Together we soar.

Company profile

Last name:

JCR Pharmaceuticals Co., Ltd.


3-19 Kasuga-cho, Ashiya, Hyogo, Japan


September 13, 1975

Paid-up capital:

JPY 9,061 million (as of March 31, 2022)

Activity area:

Manufacture, sale, purchase, import/export of pharmaceutical products, regenerative drugs and medicinal substances. Sale, purchase, import/export of medical devices and laboratory instruments.



Sysmex Company published this content on October 03, 2022 and is solely responsible for the information contained therein. Distributed by Audienceunedited and unmodified, on October 03, 2022 06:13:01 UTC.

Public now 2022


Sales 2023 411B
2,843 million
2,843 million
2023 net income 51,311M
355 million
355 million
Net cash 2023 67,713M
PER 2023 ratio 31.7x
2023 return 1.04%
Capitalization 1,625B
11,233 million
11,233 million
EV / Sales 2023 3.79x
EV / Sales 2024 3.45x
# of employees 8,771
Floating 73.0%


Duration :

Period :

Sysmex Corporation Technical Analysis Chart |  MarketScreener

Trends in Technical Analysis SYSMEX CORPORATION

Short term Middle term Long term
Tendencies Neutral Neutral Bearish

Evolution of the income statement


To buy

Medium consensus SURPASS
Number of analysts 14
Last closing price ¥7,768.00
Average target price ¥9,780.77
Average Spread / Target 25.9%

Comments are closed.